证券代码：002476 证券简称：宝莫股份 公告编号：2023-023 山东宝莫生物化工股份有限公司 关于对全资子公司提供财务资助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1.山东宝莫生物化工股份有限公司（下称"公司"）拟对全资子公司东营宝 莫环境工程有限公司（下称"宝莫环境"）、新疆宝莫环境工程有限公司（下称"新 疆宝莫"）、成都宝莫矿业有限公司（下称"成都宝莫"）、上海宝莫实业有限公司 （下称"上海宝莫"）无偿提供合计不超过人民币 4.5 亿元的财务资助额度（下 称"本次财务资助事项"），期限 3 年。 2.本次财务资助事项已经公司第六届董事会第八次会议审议通过，独立董事 对本次财务资助事项发表了同意的独立意见。 3.本议案经董事会审议通过后，还需提请股东大会审议。 一、财务资助事项的概述 2023 年 8 月 12 日公司召开第六届董事会第八次会议，审议通过了《关于对 全资子公司提供财务资助的议案》，同意公司分别对宝莫环境、新疆宝莫、成都 宝莫和上海宝莫无偿提供合计不超过人民币 4.5亿元的财务资助额度，期限3年， 主要为满 ...

山东宝莫生物化工股份有限公司 2023 年第一季度报告 证券代码：002476 证券简称：宝莫股份 公告编号：2023-012 山东宝莫生物化工股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 98,407,036.72 | 147,248,909.05 | -33.17% | | 归属于上市公司股东的净利 | -3,923,995.10 | 9,874,608.1 ...

Financial Performance - The company's operating revenue for 2022 was ¥592,284,770.21, a decrease of 9.87% compared to ¥657,160,020.80 in 2021[22]. - Net profit attributable to shareholders increased by 65.09% to ¥29,630,378.11 in 2022 from ¥17,948,109.83 in 2021[22]. - The basic earnings per share rose by 65.19% to ¥0.0484 in 2022, compared to ¥0.0293 in 2021[22]. - The total assets at the end of 2022 were ¥1,039,968,863.39, reflecting a 4.80% increase from ¥992,377,094.35 at the end of 2021[22]. - The company reported a significant cash flow deficit from operating activities of ¥78,171,438.21 in 2022, worsening by 124.57% from a deficit of ¥34,809,678.63 in 2021[22]. - The company reported a total of ¥4,549,508.02 in non-recurring gains in 2022, compared to ¥2,949,303.64 in 2021[28]. - The weighted average return on equity increased to 3.47% in 2022 from 2.16% in 2021[22]. - The company achieved operating revenue of ¥592,284,770.21, a decrease of 9.87% compared to the previous year[40]. - Total revenue for 2022 was ¥592,284,770.21, a decrease of 9.87% compared to ¥657,160,020.80 in 2021[44]. - The company reported a significant increase in revenue from commodity trading, which rose by 428.15% to ¥20,775,120.19[44]. - Domestic revenue decreased by 22.44% to ¥432,891,924.52, while international revenue increased by 61.00% to ¥159,392,845.69[44]. - The gross profit margin for chemical raw materials and chemical products manufacturing improved to 18.16%, up from 15.50% in the previous year[46]. - The company reported a total revenue of 1.5 billion in 2022, representing a year-over-year increase of 10%[99]. - The company reported a total revenue of 3.1 billion in 2022, maintaining a stable performance compared to previous years[100]. Market Strategy and Expansion - The company plans to enhance its market expansion strategy by increasing participation in international exhibitions and leveraging e-commerce platforms to penetrate markets in North America, the Middle East, and Southeast Asia[33]. - The company aims to strengthen its sales system and improve after-sales technical service capabilities to meet the strategic needs of oilfield development[33]. - The company is focusing on the development of shale oil and gas supporting products, including three types of oil reservoir development agents and offshore oil extraction agents[33]. - The company plans to continue optimizing product structure and enhancing service quality to address challenges in overseas markets[49]. - The company aims to enhance market expansion in oilfield products, focusing on surfactants and offshore oilfield additives, while also targeting water treatment and paper-making markets[84]. - The company is actively pursuing new business opportunities in the mining sector to enhance operational efficiency and profitability[85]. - The company will continue to explore sustainable development strategies and seek high-quality assets for long-term growth[85]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[99]. - Market expansion plans include entering three new international markets by the end of 2023[99]. Research and Development - The company is developing a high-salt-resistant fracturing fluid with low residue and better shear resistance, aiming to expand its product market in oil and gas extraction[60]. - The new biocatalyst application technology is expected to improve production efficiency and product quality while reducing production costs[60]. - The company is conducting industrial trials for a new type of emulsified temperature-resistant salt-reducing agent, which is anticipated to enhance product performance and market competitiveness[61]. - A dual-effect heavy oil viscosity reducer is being developed, with the goal of reducing interfacial tension and improving oil washing efficiency[60]. - The company is optimizing the catalytic reaction process for acrylamide production, which is expected to enhance product quality and reduce production costs[60]. - The development of a low molecular weight anionic drilling fluid flocculant is aimed at improving mechanical drilling speed and reducing drilling costs[61]. - The company is working on a new production process for low residual single-phase emulsion polymer, which is expected to meet industry requirements in water treatment and oil extraction[61]. - A new granulation technology is being researched to produce ultra-low molecular weight polyacrylamide, which will extend shelf life and reduce transportation costs[61]. - The company is focusing on synthesizing a high-stability acid-thickening agent that meets temperature and acid requirements for various geological conditions[61]. - R&D investment increased by 13.79% to ¥25,485,989.84, representing 4.30% of operating revenue, up from 3.41% in the previous year[62]. - The number of R&D personnel remained stable at 69, with a slight increase in the proportion of R&D staff to total employees from 14.08% to 14.62%[62]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development[103]. - The management team emphasizes the importance of innovation in product development to meet evolving market demands[104]. - The company plans to invest in research and development to support the launch of new products in the next fiscal period[103]. Governance and Management - The company has maintained a focus on risk management in its derivative trading, ensuring compliance with internal controls and regulatory requirements[77]. - The company reported no fundraising activities during the reporting period[78]. - The company has established a comprehensive procurement, production, and sales system, ensuring autonomous market operations[96]. - The board of directors and supervisory board operate independently, with no interference from the controlling shareholder[96]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate reporting of significant information[94]. - The independent directors actively participate in decision-making, ensuring fairness and objectivity[92]. - The company has established specialized committees to promote standardized operations and sustainable development[92]. - The company has a diverse management team with backgrounds in finance, auditing, and risk management[107]. - The company is focused on enhancing its governance structure through the appointment of qualified independent directors and supervisors[106]. - The company has implemented a monthly payment system for director and supervisor allowances, with performance bonuses distributed based on assessments[109]. - The board of directors held a total of 8 meetings during the reporting period, with all members attending their respective meetings without any absences[112]. - The company maintained a structured approach to internal control management, enhancing operational quality and risk prevention measures[117]. - The company has adhered to the requirements of the China Securities Regulatory Commission regarding integrity in operations, with no reported violations[121]. - The internal audit process has been deemed effective in promoting the company's operational integrity and compliance[119]. Environmental and Social Responsibility - Environmental protection expenditures totaled CNY 1,108,827.43 during the reporting period[143]. - The wastewater treatment facility has a processing capacity of 1,500 cubic meters per day and operates normally[140]. - The company implemented a rainwater and sewage diversion system in March 2022 to reduce environmental and soil pollution[140]. - The company has a waste gas treatment system in place, including a condensation absorption device for the acrylonitrile storage tank[139]. - The company has established an emergency response plan for potential environmental incidents, which has been filed with the local environmental authority[141]. - The company has a wastewater treatment agreement with Sinopec for deep processing and compliant discharge[140]. - The company has installed a chemical washing and biological deodorization system at its wastewater treatment facility[139]. - The company has ceased operation of a 40-ton/hour coal-fired steam boiler, switching to centralized heating to reduce carbon emissions[143]. - The company did not face any administrative penalties related to environmental issues during the reporting period[144]. - The company conducted 18 safety inspections in 2022, identifying 137 hazards, all of which were rectified within the designated period[146]. - There were no major safety incidents reported during the year[147]. - The company has not engaged in poverty alleviation or rural revitalization efforts during the reporting period[148]. Shareholder and Equity Information - The company reported a total of 43,575 shareholders at the end of the reporting period[187]. - The largest shareholder, Tibet Taiyi Feng Information Technology Co., Ltd., holds 96,698,030 shares, representing 15.80% of total shares[188]. - The second-largest shareholder, Wu Hao, owns 34,145,176 shares, which is 5.58% of total shares[188]. - The total number of shares after the recent changes is 612,000,000, maintaining a 100% ownership structure[185]. - The number of restricted shares decreased by 2,325, resulting in a total of 49,050 restricted shares, which is 0.01% of total shares[184]. - The unlimited sale condition shares increased by 2,325, bringing the total to 611,950,625, which accounts for 99.99% of total shares[184]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[191]. - The audit report issued by the accounting firm indicates a standard unqualified opinion, confirming that the financial statements fairly reflect the company's financial position as of December 31, 2022[199]. - The company has not reported any significant changes in the shareholding structure or any pledges of shares by major shareholders[192]. - The company has not engaged in any repurchase transactions during the reporting period[192]. - There are no preferred shares or bond-related issues reported for the company during the period[194][197].

（问题征集专题页面二维码） 山东宝莫生物化工股份有限公司（以下简称"公司"）2022 年年度报告于 2023 年 4 月 20 日披露，为使广大投资者进一步了解公司 2022 年年度报告和经 营情况，公司定于 2023 年 4 月 25 日（星期二）下午 15:00—17:00 在深圳证券 信息有限公司提供的网上平台举行公司 2022 年度报告网上说明会。 本次说明会将采用网络远程方式举行，投资者可登陆"全景•路演天下" （http://rs.p5w.net）参与本次说明会。出席本次说明会的人员有：公司董事 长陶旭城先生，财务负责人（财务总监）王姝怡女士，副总经理、董事会秘书张 世鹏先生，独立董事童利忠先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 24 日（星期一）15：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维 码，进入问题征集专题页面。 公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进行回答。欢 迎广大投资者积极参与本次网上说明会！ 证券代 ...

证券代码：002476 证券简称：宝莫股份 公告编号：2022-043 山东宝莫生物化工股份有限公司 关于参加山东辖区上市公司 2022 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，构建和谐投资者关系，山东宝莫生物化 工股份有限公司（以下简称"公司"）将参加由山东证监局联合协会等单位举办 的"山东辖区上市公司 2022 年度投资者网上集体接待日活动"，现将有关事项公 告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的网上平台举行， 广大投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与公 司互动交流，互动交流的时间为 2022 年 11 月 16 日（周三）14:00 - 16:00。 届时公司董事、财务负责人（财务总监）王姝怡女士以及副总经理、董事会 秘书张世鹏先生将通过网络在线互动的形式，与广大投资者就公司治理及社会责 任/ESG、经营状况、发展战略、风险防控、投资者保护、三季度报告等投资者关 心的问题进行交流。 欢迎广大投资者积极参与！ ...

山东宝莫生物化工股份有限公司 2022 年第三季度报告 证券代码：002476 证券简称：宝莫股份 公告编号：2022-041 1 山东宝莫生物化工股份有限公司 2022 年第三季度报告 山东宝莫生物化工股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 121,614,664.07 | -44. ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 301,387,851.40, representing a 14.71% increase compared to CNY 262,731,048.42 in the same period last year[23]. - Net profit attributable to shareholders increased by 81.95% to CNY 14,975,777.41 from CNY 8,230,726.29 year-on-year[23]. - The net profit after deducting non-recurring gains and losses rose by 89.77% to CNY 13,939,091.25 compared to CNY 7,345,310.55 in the previous year[23]. - Basic earnings per share increased by 82.84% to CNY 0.0245 from CNY 0.0134 in the same period last year[23]. - The total profit for the first half of 2022 was CNY 18,396,274.45, significantly higher than CNY 8,041,870.30 in the same period of 2021, showing an increase of approximately 128.5%[133]. - The total comprehensive income for the first half of 2022 was CNY 14,975,777.41, up from CNY 8,230,726.29 in the first half of 2021, reflecting an increase of approximately 82.5%[134]. - The company reported a net profit of CNY 14,443,506.72 for the first half of 2022, compared to a loss of CNY 532,270.69 in the same period last year[126]. - The company reported a net investment loss of ¥653,158.50, which accounted for -3.55% of total profit[40]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 1,101,975,349.91, an increase of 11.04% from CNY 992,377,094.35 at the end of the previous year[23]. - The total assets as of June 30, 2022, amounted to CNY 1,101,975,349.91, compared to CNY 992,377,094.35 at the beginning of the year, reflecting a growth of approximately 11%[126]. - Total liabilities increased to CNY 245,152,700.55 from CNY 152,395,723.08, indicating a significant rise in financial obligations[126]. - The total current liabilities increased to CNY 243,761,691.26 from CNY 150,741,415.55, indicating a rise in short-term financial commitments[126]. - The company's equity attributable to shareholders reached CNY 856,822,649.36, up from CNY 839,981,371.27, showing a slight increase in shareholder value[126]. Cash Flow - The company reported a significant decline in net cash flow from operating activities, which was CNY -81,802,866.23, compared to CNY -15,707,317.27 in the same period last year, a decrease of 420.79%[23]. - The net cash flow from operating activities for the first half of 2022 was -81,802,866.23 CNY, compared to -15,707,317.27 CNY in the same period of 2021, indicating a significant decline[139]. - The ending cash and cash equivalents balance for the first half of 2022 was 316,809,873.07 CNY, compared to 298,289,795.30 CNY at the end of the first half of 2021[140]. - The cash and cash equivalents decreased by 28.63% to -CNY 81,340,157.27 compared to -CNY 63,237,348.35 in the previous year[35]. Research and Development - Research and development expenses increased by 96.13% to CNY 15,977,438.59, primarily due to increased direct investment and outsourced R&D costs[34]. - The company has ongoing research and development efforts in new products and technologies, although specific details were not disclosed in the report[38]. - The company has established extensive cooperation with research institutions such as Tsinghua University and the Chinese Academy of Sciences, enhancing its technological innovation capabilities[32]. Market and Revenue Segments - The revenue from environmental water treatment increased by 84.31% to CNY 18,407,750.76, compared to CNY 9,987,140.64 in the previous year[36]. - The company’s revenue from oilfield chemicals was CNY 264,634,321.61, accounting for 87.81% of total revenue, with a year-on-year growth of 58.97%[36]. - Domestic revenue increased by 19.35% to ¥218,444,354, while foreign revenue rose by 20.47% to ¥82,943,497, marking a 109.57% increase in growth rate[38]. Risks and Challenges - The company faces risks related to oil price fluctuations, high customer concentration, and raw material price volatility, which could impact its business performance[4][6]. - The company faces significant risks including oil price fluctuations, high customer concentration, raw material price volatility, exchange rate risks, market expansion challenges, and safety/environmental risks[58]. - The company plans to closely monitor international oil price trends and adjust production plans accordingly to mitigate the impact of price fluctuations[59]. Corporate Governance and Shareholder Relations - The company emphasizes the protection of shareholder interests, particularly for minority shareholders, by ensuring timely and accurate information disclosure[76]. - The company has established a corporate governance structure including a shareholders' meeting, board of directors, and supervisory board[159]. - The total number of ordinary shareholders at the end of the reporting period was 47,108[110]. Environmental Initiatives - The wastewater treatment facility has a processing capacity of 1,500 cubic meters per day and is currently operational, with wastewater being treated and discharged in compliance with standards[70]. - The company has implemented a new rainwater and sewage diversion system to reduce environmental and soil pollution[69]. - The company has developed emergency response plans for potential environmental incidents, which have been filed with the local environmental protection bureau[71]. Investment and Acquisitions - The company agreed to transfer 30% equity of its subsidiary Lida Pharmaceutical to Shanghai XianDao Pharmaceutical for a transaction price of RMB 13 million[100]. - The company signed an investment intention agreement to acquire up to 20% equity in Liling Rijing Mining Development Co., Ltd. and Liling Hongbo Mining Development Co., Ltd.[102]. - The company is actively exploring strategic mergers and acquisitions to bolster its market position and operational capabilities[155]. Financial Reporting and Compliance - The financial report for the first half of 2022 was not audited[122]. - The financial statements comply with the enterprise accounting standards and reflect the company's financial position as of June 30, 2022[167]. - The company has assessed its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its sustainability[165].

山东宝莫生物化工股份有限公司 2022 年第一季度报告全文 证券代码：002476 证券简称：宝莫股份 公告编号：2022-018 山东宝莫生物化工股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 147,248,909.05 | 103,188,557.65 | 42.70% | | 归属于上市公司股东的净利润（元） | 9,874,608.10 | 203, ...

Financial Performance - The company's operating revenue for 2021 was CNY 657,160,020.80, representing a 46.91% increase compared to CNY 447,314,622.27 in 2020[18]. - The net profit attributable to shareholders for 2021 was CNY 17,948,109.83, up 36.15% from CNY 13,182,608.80 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 14,998,806.19, a 17.31% increase from CNY 12,785,450.82 in 2020[18]. - The basic earnings per share for 2021 was CNY 0.0293, reflecting a 36.28% increase from CNY 0.0215 in 2020[19]. - The total assets at the end of 2021 were CNY 992,377,094.35, a decrease of 1.75% from CNY 1,010,062,108.61 at the end of 2020[19]. - The net assets attributable to shareholders increased by 2.19% to CNY 839,981,371.27 from CNY 822,017,035.36 in 2020[19]. - The net cash flow from operating activities was negative at CNY -34,809,678.63, a decline of 207.05% compared to CNY 32,516,430.47 in 2020[18]. - The weighted average return on equity for 2021 was 2.16%, up from 1.62% in 2020[19]. Revenue Breakdown - The chemical business generated revenue of 473,776,207.52 yuan, with a cost of 400,336,018.71 yuan, reflecting increases of 18.71% and 18.03% respectively[38]. - The environmental water treatment business reported revenue of 28,462,555.70 yuan, a 204.22% increase, with costs rising by 129.44% to 23,308,614.88 yuan[38]. - Domestic revenue accounted for 84.93% of total revenue, amounting to ¥558,155,667.17, which is a 58.34% increase year-on-year[43]. - The revenue from photovoltaic power generation decreased by 37.74% to ¥23,561,152.51, down from ¥37,842,627.69 in 2020[43]. - The sales volume of photovoltaic power generation decreased by 37.22% to 36,730,000 kWh in 2021 from 58,510,000 kWh in 2020[50]. Market Strategy and Expansion - The company is a leading supplier of polyacrylamide, primarily serving the oil and gas development and wastewater treatment markets[30]. - The company has expanded its market presence in North America, Southeast Asia, Central Asia, and the Middle East through e-commerce and international exhibitions[30]. - The company aims to enhance its overall profitability and sustainable development capabilities by focusing on technological innovation and market expansion[29]. - The company has adjusted its market strategy to stabilize its main business amidst increasing competition in the chemical industry[30]. - The company plans to strengthen market expansion in oilfield products, focusing on surfactants, temperature-resistant and salt-resistant polyacrylamide, and offshore oil extraction agents to improve profitability[89]. Research and Development - The company filed 12 patents and received 4 authorized patents during the year, bringing the total to 28 patents[36]. - The company’s R&D expenses increased by 25% year-on-year, reflecting ongoing investment in innovation[39]. - The company is focusing on the development of a new type of anionic long-fiber papermaking additive to enhance paper quality during production[62]. - The company is conducting industrial trials for a high-efficiency flocculant specifically for aluminum production, which is expected to enhance product quality and market reach[60]. - The company's R&D investment increased by 25.00% to ¥22,397,556.64 in 2021 from ¥17,918,195.32 in 2020[64]. Management and Governance - The company has established a comprehensive governance structure, including various committees to ensure effective decision-making and compliance with regulations[96]. - The company has committed to avoiding any competition with its controlling shareholder, ensuring a clear operational boundary[101]. - The company appointed Zhao Gang as the new General Manager on April 2, 2021, following the resignation of the previous General Manager Wu Feng[107]. - The company has established a performance-based compensation system for its internal directors and senior management[116]. - The board of directors held a total of 22 meetings during the reporting period, with significant resolutions including the approval of the 2021 annual report and the establishment of wholly-owned subsidiaries[119][120]. Environmental and Safety Management - The company has established a wastewater treatment facility with a processing capacity of 1,200 cubic meters per day, ensuring compliance with environmental standards[147]. - The company operates a 40T/H boiler with desulfurization and denitrification equipment, achieving ultra-low emissions[147]. - The company has implemented an emergency response plan for environmental incidents, which has been filed with the local environmental protection bureau[149]. - The company has committed to maintaining zero safety and environmental accidents throughout the year by enhancing safety and environmental management practices[89]. - In 2021, the company allocated 3.7 million yuan for safety production expenses, with actual usage at 3.6843 million yuan, indicating a focus on safety management[153]. Financial Management - The company reported a loss in investment income of -¥2,263,497.03, accounting for -12.79% of total profit[68]. - The company has established an independent financial department with its own accounting system and management practices, ensuring financial independence[101]. - The company has not reported any significant changes in its accounting policies for derivatives compared to the previous reporting period[81]. - The company has not faced any administrative penalties for environmental issues during the reporting period[150]. - The company has not engaged in poverty alleviation or rural revitalization efforts during the reporting period[154].

Financial Performance - The company's operating revenue for 2021 was CNY 657,160,020.80, representing a 46.91% increase compared to CNY 447,314,622.27 in 2020[19] - The net profit attributable to shareholders for 2021 was CNY 17,948,109.83, up 36.15% from CNY 13,182,608.80 in the previous year[19] - The net profit after deducting non-recurring gains and losses was CNY 14,998,806.19, reflecting a 17.31% increase from CNY 12,785,450.82 in 2020[19] - The basic earnings per share for 2021 was CNY 0.0293, a 36.28% increase from CNY 0.0215 in 2020[20] - The total assets at the end of 2021 were CNY 992,377,094.35, a decrease of 1.75% from CNY 1,010,062,108.61 at the end of 2020[20] - The net assets attributable to shareholders increased by 2.19% to CNY 839,981,371.27 at the end of 2021, compared to CNY 822,017,035.36 at the end of 2020[20] - The net cash flow from operating activities was negative CNY 34,809,678.63, a decline of 207.05% from CNY 32,516,430.47 in 2020[19] - The weighted average return on equity for 2021 was 2.16%, up from 1.62% in 2020[20] Revenue Breakdown - The chemical business generated revenue of CNY 473,776,207.52, with a cost of CNY 400,336,018.71, reflecting increases of 18.71% and 18.03% respectively[39] - The water treatment business reported revenue of CNY 28,462,555.70, a 204.22% increase, with costs rising by 129.44% to CNY 23,308,614.88, marking a turnaround to profitability[39] - The revenue from the chemical raw materials and chemical products manufacturing industry was ¥473,776,207.52, accounting for 72.09% of total revenue, with a year-on-year growth of 18.71%[44] - The revenue from environmental water treatment surged by 204.22% to ¥28,462,555.70, increasing its share of total revenue to 4.33%[44] Cash Flow and Investments - The net cash flow from operating activities turned negative at approximately CNY -34.81 million, a decrease of 207.05% from a positive CNY 32.52 million in the previous year[67] - Investment activities generated a net cash inflow of approximately CNY 119.47 million, a significant increase of 1,254.86% from CNY 8.82 million in 2020[67] - The company's cash and cash equivalents increased by approximately CNY 36.62 million, a 225.74% improvement from a decrease of CNY -29.13 million in the previous year[67] Research and Development - The company filed 12 patents and received 4 patents in the reporting year, bringing the total to 28 patents[33] - The company's research and development expenses increased by 25.00%, rising from 17,918,195.32 yuan in 2020 to 22,397,556.64 yuan in 2021[60] - The number of R&D personnel remained stable at 69, accounting for 14.08% of the total workforce in 2021, a slight decrease from 14.65% in 2020[65] - Development of a new salt-resistant polymer fracturing fluid system is underway, aimed at expanding the company's product market[61] Market Expansion and Strategy - The company aims to enhance overall profitability and sustainable development by focusing on technological innovation, market expansion, and management improvement[30] - The company has implemented strategies to stabilize its main business while exploring new business opportunities amid a competitive chemical industry[31] - The company plans to enhance its product structure and upgrade product performance to address challenges in overseas markets, including trade sanctions and shipping difficulties[50] - The company plans to enhance market expansion in oilfield products, focusing on surfactants and offshore oilfield additives, while also targeting water treatment and paper-making markets[92] Governance and Management - The company has established a complete independent financial management system, ensuring no financial interference from the controlling shareholder[104] - The company has a fully independent operational structure, with no overlapping personnel with the controlling shareholder[104] - The company has implemented effective internal control measures to enhance management efficiency and risk prevention capabilities[102] - The company has a diverse board composition, with a mix of independent and internal directors, promoting a balanced approach to governance[121] Environmental and Safety Management - The company has established a wastewater treatment facility with a capacity of 1,200 cubic meters per day, which is currently operating normally[150] - The company has implemented ultra-low emission modifications for its 40T/H boiler, which is equipped with desulfurization and denitrification devices[150] - The company has committed to maintaining shareholder interests through regular information disclosure and investor relations activities[154] - The company emphasizes the importance of safety and environmental protection, aiming for zero safety incidents throughout the year[92] Risks and Challenges - The company faces risks related to oil price fluctuations, high customer concentration, and raw material price volatility, which could impact its financial performance[94] - The company has reported various risks faced during operations, which are detailed in the management discussion and analysis section[4] Employee and Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 919.94 million[120] - The performance-based compensation for internal directors and executives is determined based on operational performance, reflecting the company's commitment to aligning pay with performance[119] - The company has implemented a performance-based compensation system, aligning employee incentives with company performance[136] Shareholder and Board Activities - The company held its annual shareholders' meeting on May 13, 2021, with a participation rate of 16.16%[106] - The board of directors convened nine meetings in 2021, discussing various important matters including the 2020 annual report and the 2021 first-quarter report[101] - The company has experienced changes in its board of directors, with multiple resignations and new appointments in 2021[110] Financial Reporting and Compliance - The company reported zero significant defects in financial reporting and internal controls for the year 2021[146] - The company has a complete governance structure in place, ensuring compliance with laws and regulations, with no serious violations reported[145] - The company has not faced any penalties from securities regulatory agencies in the past three years[118]